Kinrix

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Acellular PertussisDiphtheriaMeasles-Mumps-RubellaTetanus

Phase 3

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

CompletedNCT01621802

GlaxoSmithKlineMeasles-Mumps-Rubella

Start: 2012-06-21End: 2015-11-09Updated: 2019-11-25

Unknown Phase

Duration of Protection: GSK DTaP Vaccines

CompletedNCT02447978

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Tetanus

Start: 2015-02-28End: 2015-06-30Updated: 2015-11-02

Related Papers

A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration

Human Vaccines & Immunotherapeutics2019-02-2014 citations

Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine

Vaccine2017-05-1342 citations